|
IL68769A
(en)
*
|
1983-05-23 |
1986-02-28 |
Hadassah Med Org |
Pharmaceutical compositions containing insulin for oral administration
|
|
US5472710A
(en)
|
1988-04-16 |
1995-12-05 |
Schwarz Pharma Ag |
Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
|
|
GB8812490D0
(en)
|
1988-05-26 |
1988-06-29 |
Agricultural & Food Res |
Delayed release formulations
|
|
IT1230576B
(it)
|
1988-10-20 |
1991-10-28 |
Angeli Inst Spa |
Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
|
|
IT1246382B
(it)
|
1990-04-17 |
1994-11-18 |
Eurand Int |
Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
|
|
IL98087A
(en)
|
1990-05-04 |
1996-11-14 |
Perio Prod Ltd |
Preparation for dispensing drugs in the colon
|
|
US5156850A
(en)
|
1990-08-31 |
1992-10-20 |
Alza Corporation |
Dosage form for time-varying patterns of drug delivery
|
|
IT1245889B
(it)
|
1991-04-12 |
1994-10-25 |
Alfa Wassermann Spa |
Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
|
|
IT1245891B
(it)
|
1991-04-12 |
1994-10-25 |
Alfa Wassermann Spa |
Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
|
|
IT1260505B
(it)
|
1992-06-01 |
1996-04-09 |
Poli Ind Chimica Spa |
Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
|
|
US5914132A
(en)
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
US5651983A
(en)
|
1993-02-26 |
1997-07-29 |
The Procter & Gamble Company |
Bisacodyl dosage form for colonic delivery
|
|
JP3725539B2
(ja)
|
1993-02-26 |
2005-12-14 |
大正製薬株式会社 |
ビサコジル剤形
|
|
US5656290A
(en)
|
1993-02-26 |
1997-08-12 |
The Procter & Gamble Company |
Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
|
|
US5843479A
(en)
|
1993-02-26 |
1998-12-01 |
The Procter & Gamble Company |
Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
|
|
US5686105A
(en)
|
1993-10-19 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
|
IT1265074B1
(it)
*
|
1993-05-18 |
1996-10-30 |
Istituto Biochimico Italiano |
Composizione farmaceutica a lento rilascio contenente come sostanza attiva un acido biliare
|
|
US5514663A
(en)
|
1993-10-19 |
1996-05-07 |
The Procter & Gamble Company |
Senna dosage form
|
|
JP3725542B2
(ja)
|
1993-10-19 |
2005-12-14 |
大正製薬株式会社 |
ピコサルフェート剤形
|
|
US5637319A
(en)
|
1995-03-01 |
1997-06-10 |
Takada; Kanji |
Controlled-release preparations
|
|
US6039975A
(en)
|
1995-10-17 |
2000-03-21 |
Hoffman-La Roche Inc. |
Colon targeted delivery system
|
|
US5763435A
(en)
|
1995-11-21 |
1998-06-09 |
Children's Hospital Medical Center |
Sulfate conjugates of ursodeoxycholic acid, and their beneficial use in inflammatory disorders
|
|
US5840332A
(en)
|
1996-01-18 |
1998-11-24 |
Perio Products Ltd. |
Gastrointestinal drug delivery system
|
|
US6231888B1
(en)
|
1996-01-18 |
2001-05-15 |
Perio Products Ltd. |
Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
|
|
US5846983A
(en)
|
1996-02-09 |
1998-12-08 |
Mayo Foundation For Medical Education And Research |
Colonic delivery of nicotine to treat inflammatory bowel disease
|
|
CA2294988C
(en)
|
1997-07-01 |
2015-11-24 |
Isis Pharmaceuticals Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
|
US6074689A
(en)
|
1998-03-10 |
2000-06-13 |
Immucell Corporation |
Colonic delivery of protein or peptide compositions
|
|
US6096731A
(en)
|
1998-06-24 |
2000-08-01 |
Institute For Drug Research, Inc. |
Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
|
|
WO2000016784A1
(en)
|
1998-09-21 |
2000-03-30 |
Amato Pharmaceutical Products, Ltd. |
Oral drug delivery system for enhancing the bioavailability of activated glycyrrhetin
|
|
US6326364B1
(en)
|
1999-02-08 |
2001-12-04 |
Cedars-Sinai Medical Center |
Use of 5-aminosalicylates as antimicrobial agents
|
|
SE9901387D0
(sv)
|
1999-04-19 |
1999-04-19 |
Astra Ab |
New pharmaceutical foromaulations
|
|
US6309663B1
(en)
*
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
EP1095650A1
(en)
|
1999-10-29 |
2001-05-02 |
Universiteit Leiden |
Double phase time-controlled release system
|
|
US7070803B2
(en)
|
2000-03-31 |
2006-07-04 |
Nycomed Austria Gmbh |
Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine
|
|
CN1141974C
(zh)
|
2000-06-07 |
2004-03-17 |
张昊 |
结肠定位释放的口服生物制剂
|
|
US8263112B2
(en)
|
2000-11-20 |
2012-09-11 |
Sorbent Therapeutics, Inc. |
In vivo use of water absorbent polymers
|
|
US6444477B1
(en)
|
2000-11-28 |
2002-09-03 |
Pharmagene Laboratories Limited |
Assay method for detecting 5-HT2B antagonists
|
|
US20030124196A1
(en)
*
|
2001-08-22 |
2003-07-03 |
Susan Weinbach |
Pulsatile release compositions and methods for enhanced intestinal drug absorption
|
|
US20030083286A1
(en)
*
|
2001-08-22 |
2003-05-01 |
Ching-Leou Teng |
Bioadhesive compositions and methods for enhanced intestinal drug absorption
|
|
JP2003160496A
(ja)
*
|
2001-11-27 |
2003-06-03 |
Minofuaagen Seiyaku:Kk |
グリチルリチン経口投与剤
|
|
US9149439B2
(en)
|
2005-03-21 |
2015-10-06 |
Sandoz Ag |
Multi-particulate, modified-release composition
|
|
WO2007019888A2
(en)
|
2005-08-12 |
2007-02-22 |
Ctg Pharma S.R.L. |
Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
|
|
US8080579B2
(en)
|
2005-10-03 |
2011-12-20 |
The Regents Of The University Of Michigan |
Compositions and methods for treatment of inflammatory bowel disease
|
|
US20080004237A1
(en)
|
2006-02-23 |
2008-01-03 |
Tam Joemy C |
Polysacchocride prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for galectin-3 expressing cancers
|
|
JP2010502591A
(ja)
*
|
2006-09-04 |
2010-01-28 |
パナセア バイオテック リミテッド |
プログラム可能な浮揚性送達技術
|
|
US8273376B2
(en)
|
2006-11-17 |
2012-09-25 |
Da Volterra |
Colonic delivery of metallo-dependent enzymes
|
|
EP2143424A4
(en)
|
2007-03-26 |
2013-07-31 |
Teikoku Seiyaku Kk |
ORAL PHARMACEUTICAL PREPARATION FOR SPECIFIC DELIVERY TO THE COLON
|
|
ES2393814T3
(es)
|
2007-04-04 |
2012-12-28 |
Sigmoid Pharma Limited |
Una composición farmacéutica oral
|
|
US10242888B2
(en)
|
2007-04-27 |
2019-03-26 |
Applied Materials, Inc. |
Semiconductor processing apparatus with a ceramic-comprising surface which exhibits fracture toughness and halogen plasma resistance
|
|
WO2009038591A1
(en)
|
2007-09-17 |
2009-03-26 |
Yale University |
Bile salt colloids and methods of making and using thereof
|
|
WO2009048289A2
(en)
|
2007-10-10 |
2009-04-16 |
Hanall Pharmaceutical Company. Ltd |
Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid
|
|
US20090246301A1
(en)
|
2008-03-31 |
2009-10-01 |
Ehrenpreis Ben Z |
Method for treating irritable bowel syndrome and other functional gastrointestinal disorders
|
|
KR101018894B1
(ko)
|
2008-08-27 |
2011-03-04 |
근화제약주식회사 |
체내 흡수가 증진된 탈니플루메이트 함유 서방정
|
|
CA2744697C
(en)
|
2008-11-26 |
2016-06-21 |
Satiogen Pharmaceuticals, Inc. |
Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
|
|
US20110268794A1
(en)
|
2009-01-09 |
2011-11-03 |
Camilleri Michael L |
Methods and materials for delivering bile acids
|
|
WO2012151252A2
(en)
|
2011-05-02 |
2012-11-08 |
Biokier, Inc. |
Composition and method for treatment of diabetes
|
|
KR20110120866A
(ko)
|
2009-01-12 |
2011-11-04 |
바이오키어 인코포레이티드 |
당뇨병 치료 조성물 및 치료방법
|
|
US8717032B2
(en)
|
2009-01-28 |
2014-05-06 |
Telefonaktiebolaget L M Ericsson (Publ) |
Electronic circuit breaker and a method of providing protection switching
|
|
ES2530049T3
(es)
|
2009-05-18 |
2015-02-26 |
Sigmoid Pharma Limited |
Composición que comprende gotas de aceite
|
|
WO2012012902A1
(en)
|
2010-07-28 |
2012-02-02 |
Msi Methylation Sciences Inc. |
S-adenosylmethionine formulations with enhanced bioavailability
|
|
US20110027342A1
(en)
|
2009-07-28 |
2011-02-03 |
Msi Methylation Sciences, Inc. |
S-adenosylmethionine formulations with enhanced bioavailability
|
|
US9301938B2
(en)
|
2009-09-23 |
2016-04-05 |
Biokier, Inc. |
Composition and method for treatment of diabetes
|
|
WO2011075539A2
(en)
|
2009-12-18 |
2011-06-23 |
Satiogen Pharmaceuticals, Inc. |
Treatment of obesity or diabetes with bile acid sequestrants
|
|
ES2552657T3
(es)
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
|
DK2637646T3
(en)
|
2010-11-08 |
2016-08-29 |
Albireo Ab |
PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
|
|
EP2661266B1
(en)
|
2011-01-07 |
2020-09-16 |
Anji Pharma (US) LLC |
Chemosensory receptor ligand-based therapies
|
|
US8796338B2
(en)
|
2011-01-07 |
2014-08-05 |
Elcelyx Therapeutics, Inc |
Biguanide compositions and methods of treating metabolic disorders
|
|
WO2012097155A1
(en)
|
2011-01-14 |
2012-07-19 |
Chiasma Inc. |
Improved pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof
|
|
US20120276056A1
(en)
|
2011-04-26 |
2012-11-01 |
Wieslaw Janusz Bochenek |
Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
|
|
EP2800562A2
(en)
|
2012-01-06 |
2014-11-12 |
Elcelyx Therapeutics, Inc. |
Compositions and methods for treating metabolic disorders
|
|
KR20190120430A
(ko)
|
2012-01-06 |
2019-10-23 |
엘셀릭스 테라퓨틱스 인코포레이티드 |
바이구아나이드 조성물 및 대사 장애를 치료하는 방법
|
|
EP3187171B1
(en)
*
|
2012-04-30 |
2024-09-25 |
Tillotts Pharma AG |
A delayed release drug formulation
|
|
US20150174076A1
(en)
*
|
2012-06-14 |
2015-06-25 |
Entrega, Inc. |
Mucoadhesive devices for delivery of active agents
|
|
HK1210825A1
(en)
|
2012-07-11 |
2016-05-06 |
Elcelyx Therapeutics, Inc. |
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
|
|
US20140112985A1
(en)
|
2012-10-22 |
2014-04-24 |
Polonez Therapeutics Llc |
Method of prevention and treatment of clostridium difficile infection
|
|
WO2014070769A1
(en)
*
|
2012-10-29 |
2014-05-08 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for treating mucosal tissue disorders
|
|
AU2014239883B2
(en)
*
|
2013-03-14 |
2019-01-17 |
Therabiome, Llc |
Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
|
|
JP6396992B2
(ja)
|
2013-04-05 |
2018-09-26 |
ヌメディー， インコーポレイテッド |
消化器系疾患およびその他の疾患の処置
|
|
CN104739845A
(zh)
*
|
2013-12-26 |
2015-07-01 |
上海医学生命科学研究中心有限公司 |
鹅去氧胆酸及其用途
|
|
US10182993B2
(en)
|
2015-04-06 |
2019-01-22 |
Patheon Softgels Inc. |
Compositions for colonic delivery of drugs
|
|
US20180193621A1
(en)
*
|
2015-06-30 |
2018-07-12 |
Entrega Inc. |
Device for oral delivery of active agents
|
|
US10864170B2
(en)
|
2015-09-04 |
2020-12-15 |
Yale University |
Polymeric bile acid nanocompositions targeting the pancreas and colon
|
|
IL243707A0
(en)
|
2016-01-20 |
2016-05-01 |
Galmed Res And Dev Ltd |
Treatment to regulate the microbiota in the intestine
|
|
CN108601739B
(zh)
|
2016-02-09 |
2022-01-04 |
阿尔比里奥公司 |
考来烯胺丸剂及其制备方法
|
|
WO2017138878A1
(en)
|
2016-02-09 |
2017-08-17 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
ES2874669T3
(es)
|
2016-02-09 |
2021-11-05 |
Albireo Ab |
Formulación oral de colestiramina y uso de la misma
|
|
CA3018589A1
(en)
|
2016-03-29 |
2017-10-05 |
Colonaryconcepts Llc |
Formulations for treating constipation
|
|
WO2018213204A1
(en)
|
2017-05-15 |
2018-11-22 |
Axial Biotherapeutics, Inc. |
Inhibitors of microbially induced amyloid
|
|
EP3664782B1
(en)
|
2017-08-09 |
2025-01-29 |
Albireo AB |
Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
|
|
CN111032019B
(zh)
|
2017-08-09 |
2022-07-05 |
阿尔比里奥公司 |
考来烯胺颗粒、口服考来烯胺制剂及其用途
|
|
US20210290593A1
(en)
|
2018-07-11 |
2021-09-23 |
Duke University |
Use of sustained-release 5-hydroxytryptophan in treating gastrointestinal disorders
|
|
US20200046758A1
(en)
|
2018-08-09 |
2020-02-13 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US11007142B2
(en)
|
2018-08-09 |
2021-05-18 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US10722457B2
(en)
|
2018-08-09 |
2020-07-28 |
Albireo Ab |
Oral cholestyramine formulation and use thereof
|
|
US20200046757A1
(en)
|
2018-08-09 |
2020-02-13 |
Albireo Ab |
Cholestyramine pellets, oral cholestyramine formulations, and uses thereof
|
|
US11524029B2
(en)
|
2018-08-13 |
2022-12-13 |
Viscera Labs, Inc. |
Therapeutic composition and methods
|
|
EP3646857A1
(en)
|
2018-11-01 |
2020-05-06 |
Evonik Operations GmbH |
Colonic delivery system for microorganisms
|